Metaraminol

Phase 3Small molecule

UUniversity of Sao Paulo General Hospital

Metaraminol is one of 68 small molecule programs targeting Hypotension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypotensionActive, not recruiting

Cesarean SectionActive, not recruiting

HypotensionPhase 3

Active, not recruiting

Cesarean SectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Metaraminol

UUniversity of Sao Paulo General Hospital

Phase 3

1 2

Marcaine

IInnocoll

Preclinical

21 3

Pitocin

RRetrophin

Preclinical

16 4

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 5

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 6

Dynastat

Pfizer

Preclinical

1 7

Duragesic

CCephalon

Preclinical

6 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 9

Catapres

Boehringer Ingelheim

Preclinical

4 10

Ancef

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cesarean Section1 trial

Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section

Completed·FFederal University of São Paulo·Phase 2·NCT01108874·48 enrolled

Cardiac1 trial

Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation

Unknown status·UUniversity of Sao Paulo General Hospital·N/A·NCT02245191·60 enrolled

Cesarean Delivery1 trial

Effect of Three Weight-adjusted Vasopressors for Elective Cesarean Delivery

Completed·XXuzhou Medical University·Phase 4·NCT04991662·78 enrolled

Hypotension1 trial

Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean

Withdrawn·IInstituto Materno Infantil Prof. Fernando Figueira·Phase 3·NCT01451060

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Metaraminol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metaraminol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metaraminol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Sao Paulo General Hospital

Metaraminol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cesarean Section1 trial

Cardiac1 trial

Cesarean Delivery1 trial

Hypotension1 trial

References

Drug Info

Quick Facts

Related News